drugset / Trial / NCT04552327
5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis
Phase 3
Completed
631 enrolled
Infectopharm Arzneimittel GmbH
Gesellschaft für Therapieforschung mbH · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.
Timeline
- Start
- 2020-10-14
- Primary completion
- 2023-01-24
- Completion
- 2023-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diclofenac | Other / unclassified | 3 % | Topical |